BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sun L, Li PB, Yao YF, Xiu AY, Peng Z, Bai YH, Gao YJ. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2018; 24(10): 1120-1133 [PMID: 29563756 DOI: 10.3748/wjg.v24.i10.1120]
URL: https://www.wjgnet.com/1007-9327/full/v24/i10/1120.htm
Number Citing Articles
Yuhong Jiang, Xin Zhuo, Yue Wu, Xiujuan Fu, Canquan Mao. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expressionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research 2022; 1869(1): 119144 doi: 10.1016/j.bbamcr.2021.119144
Jordan C. LeSarge, Pierre Thibeault, Lihai Yu, Marina D. Childs, Victor M. Mirka, Qi Qi, Matthew S. Fox, Michael S. Kovacs, Rithwik Ramachandran, Leonard G. Luyt. Protease-activated receptor 2 (PAR2)-targeting peptide derivatives for positron emission tomography (PET) imagingEuropean Journal of Medicinal Chemistry 2023; 246: 114989 doi: 10.1016/j.ejmech.2022.114989
Kiman Kim, Jinyong Lee, Sungho Ghil. The regulators of G protein signaling RGS 16 and RGS 18 inhibit protease‐activated receptor 2/Gi/o signaling through distinct interactions with Gα in live cells FEBS Letters 2018; 592(18): 3126 doi: 10.1002/1873-3468.13220
Kaushik Das, Subhojit Paul, Arpana Singh, Arnab Ghosh, Abhishek Roy, Shabbir Ahmed Ansari, Ramesh Prasad, Ashis Mukherjee, Prosenjit Sen. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transitionJournal of Biological Chemistry 2019; 294(37): 13681 doi: 10.1074/jbc.RA119.008619
Kenjiro Kaji, Noriyuki Kaji, Masatoshi Hori, Kosei Sakai, Tomohiro Yonezawa, Shingo Maeda. Protease-Activated Receptor-2 Is Associated With Adverse Outcomes in Canine Mammary CarcinomaVeterinary Pathology 2021; 58(1): 53 doi: 10.1177/0300985820963087
Nisha R. Pawar, Marguerite S. Buzza, Toni M. Antalis. Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2–Mediated Signaling: Co-Conspirators in Cancer ProgressionCancer Research 2019; 79(2): 301 doi: 10.1158/0008-5472.CAN-18-1745
Juncheng Guo, Min Guo, Jinfang Zheng. Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK PathwayCancer Management and Research 2021; : 773 doi: 10.2147/CMAR.S281969
Yuhong Jiang, Xin Zhuo, Xiujuan Fu, Yue Wu, Canquan Mao. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR TransactivationFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.625289
P SUHAJ, T OLEJAR, R MATEJ. PAR2: The Cornerstone of Pancreatic DiseasesPhysiological Research 2022; : 583 doi: 10.33549/physiolres.934931
Hendrik Ungefroren, Frank Gieseler, Roland Kaufmann, Utz Settmacher, Hendrik Lehnert, Bernhard Rauch. Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and CancerInternational Journal of Molecular Sciences 2018; 19(6): 1568 doi: 10.3390/ijms19061568
Yuhong Jiang, Junxian Lim, Kai‐Chen Wu, Weijun Xu, Jacky Y. Suen, David P. Fairlie. PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFRBritish Journal of Pharmacology 2021; 178(4): 913 doi: 10.1111/bph.15332
Y. Bareche, D. Kelly, F. Abbas-Aghababazadeh, M. Nakano, P.N. Esfahani, D. Tkachuk, H. Mohammad, R. Samstein, C.-H. Lee, L.G.T. Morris, P.L. Bedard, B. Haibe-Kains, J. Stagg. Leveraging big data of immune checkpoint blockade response identifies novel potential targetsAnnals of Oncology 2022; 33(12): 1304 doi: 10.1016/j.annonc.2022.08.084